Non-Hodgkin lymphoma

HealthWell Foundation Opens New Fund to Assist B-Cell Lymphoma Patients

Monday, August 3, 2020 - 3:31pm

The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms.

Key Points: 
  • The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms.
  • "Phenomenal advances in treatment for B-cell lymphoma are only useful when patients can afford them," said Don Liss, MD, HealthWell Foundation Board Member.
  • Krista Zodet, HealthWell Foundation President, commented on the fund, "People living with B-cell lymphoma can be faced with a multitude of challenges when it comes to managing their disease.
  • A nationally recognized, independent non-profit organization founded in 2003, the HealthWell Foundation has served as a safety net across over 70 disease areas for more than 500,000 underinsured patients.

DGAP-News: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Saturday, August 1, 2020 - 1:00am

The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy.

Key Points: 
  • The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy.
  • "The FDA approval of Monjuvi in combination with lenalidomide helps address an urgent unmet medical need for patients with relapsed or refractory DLBCL in the United States," said Herv Hoppenot, Chief Executive Officer, Incyte.
  • "Today's FDA decision offers new hope for patients with this aggressive form of DLBCL who progressed during or after first-line therapy."
  • The FDA previously granted Fast Track and Breakthrough Therapy Designation for the combination of Monjuvi and lenalidomide in relapsed or refractory DLBCL.

FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Saturday, August 1, 2020 - 12:51am

The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy.

Key Points: 
  • The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy.
  • The FDA approval of Monjuvi in combination with lenalidomide helps address an urgent unmet medical need for patients with relapsed or refractory DLBCL in the United States, said Herv Hoppenot, Chief Executive Officer, Incyte.
  • The FDA approval was based on data from the MorphoSys-sponsored Phase 2 L-MIND study, an open label, multicenter, single arm trial of Monjuvi in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL.
  • The FDA previously granted Fast Track and Breakthrough Therapy Designation for the combination of Monjuvi and lenalidomide in relapsed or refractory DLBCL.

Peripheral T-Cell Lymphoma (PTCL) Market and Epidemiology Forecast, 2030 - ResearchAndMarkets.com

Thursday, July 30, 2020 - 10:35am

The "Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The PTCL market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM PTCL market size from 2017 to 2030.
  • The drug candidate is in Phase II stage of development for Peripheral T-cell lymphoma (PTCL) in Japan.
  • Adcetris and Istodax (Romidepsin) for the first line treatment of PTCL is projected to lead the market with the highest market share in 2030.

U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma

Friday, July 24, 2020 - 6:25pm

This approval marks the first CAR T cell therapy approved for mantle cell lymphoma patients and represents a new frontier in the treatment of this disease, said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation.

Key Points: 
  • This approval marks the first CAR T cell therapy approved for mantle cell lymphoma patients and represents a new frontier in the treatment of this disease, said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation.
  • Todays news builds upon this progress and provides hope to mantle cell patients and their loved ones.
  • Manufacturing speed is especially critical for patients with advanced disease, who are very ill and at risk for quick progression.
  • Kite Konnect provides support for eligible patients receiving Yescarta and Tecartus, and it provides information for the healthcare teams supporting their patients.

ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib

Friday, July 17, 2020 - 12:15pm

We are pleased to have dosed the first patient in the pivotal Phase 2 portion of this trial as we continue advancing Lonca as both a single agent and in combination with other therapies for patients with non-Hodgkin lymphoma.

Key Points: 
  • We are pleased to have dosed the first patient in the pivotal Phase 2 portion of this trial as we continue advancing Lonca as both a single agent and in combination with other therapies for patients with non-Hodgkin lymphoma.
  • The 161-patient Phase 1/2 open-label, single-arm clinical trial is evaluating the safety and efficacy of Lonca in combination with ibrutinib in patients with relapsed or refractory DLBCL or MCL.
  • The Phase 2 portion of the trial will enroll three cohorts: non-germinal center B-cell-like (non-GCB) DLBCL, GCB DLBCL and MCL.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Thursday, July 9, 2020 - 11:45am

We look forward to working with the FDA to bring KEYTRUDA to more patients with classical Hodgkin lymphoma after initial treatment.

Key Points: 
  • We look forward to working with the FDA to bring KEYTRUDA to more patients with classical Hodgkin lymphoma after initial treatment.
  • Classical Hodgkin lymphoma accounts for more than nine in 10 cases of Hodgkin lymphoma in developed countries.
  • KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.

Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV) 2020: Industry and Pipeline Assessment - ResearchAndMarkets.com

Thursday, July 2, 2020 - 2:54pm

The "Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) market.
  • A detailed picture of the Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) pipeline landscape is provided, which includes the disease overview and Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) treatment guidelines.
  • The assessment part of the report embraces in-depth Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) commercial assessment and clinical assessment of the Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) pipeline products from the pre-clinical developmental phase to the marketed phase.

XPOVIO® (selinexor) Now Approved for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Available from Onco360

Wednesday, June 24, 2020 - 7:00pm

Onco360 is excited to be selected as a specialty pharmacy provider for XPOVIO patients, said Paul Jardina, President and CEO, Onco360.

Key Points: 
  • Onco360 is excited to be selected as a specialty pharmacy provider for XPOVIO patients, said Paul Jardina, President and CEO, Onco360.
  • The recent approval of XPOVIO unlocks a new treatment option for relapsed or refractory DLBCL patients who have failed previous lines of treatment.
  • As a provider of this key treatment, Onco360 can support the highly specialized needs of relapsed or refractory DLBCL patients and their physicians across the states.
  • Onco360 is the largest independent Oncology Pharmacy and clinical support services company in the country.

TAZVERIK™ (tazemetostat) Now Approved for the Treatment of Relapsed/Refractory Follicular Lymphoma, Available from Onco360

Monday, June 22, 2020 - 2:00pm

The approval of TAZVERIK as a treatment option for patients with relapsed/refractory follicular lymphoma is an important advancement in fighting this devastating disease, said Paul Jardina, President and CEO, Onco360.

Key Points: 
  • The approval of TAZVERIK as a treatment option for patients with relapsed/refractory follicular lymphoma is an important advancement in fighting this devastating disease, said Paul Jardina, President and CEO, Onco360.
  • As a specialty oncology pharmacy, we are committed to improving the lives of cancer patients suffering from follicular lymphoma.
  • Follicular lymphoma is the second-most common type of non-Hodgkin lymphoma and is considered to be indolent, yet incurable.
  • According to the National Comprehensive Cancer Network Guidelines for B-Cell Lymphomas, approximately 12,600 patients are diagnosed with follicular lymphoma on an annual basis.